In CRC, the methylation status of multiple promoters can be predicted through knowledge of BRAF and, to a lesser extent, KRAS activating mutations, indicating that these mutations are closely ...
Colorectal cancer (CRC), a type of cancer that affects the large intestine and rectum, is one of the leading causes of cancer-related deaths worldwide. The mutational landscape of CRC is ...
A review article led by researchers from the B·ARGO group at the Germans Trias i Pujol Research Institute (IGTP) and from the Medical Oncology Department of the Catalan Institute of Oncology (ICO) in ...
Patients with metastatic colorectal cancer (mCRC) harboring BRAF V600E mutations benefited from first-line treatment with the targeted therapies encorafenib and cetuximab plus a mFOLFOX6 chemotherapy ...
The BRAF mutation in lung cancer means that your cancer started due to a change in the BRAF gene. It may affect your treatment options and outlook. The BRAF gene is partially responsible for cell ...
NEW YORK, Sept 14 (Reuters) - Pfizer (PFE.N), opens new tab is trying to increase doctor awareness of and testing for a rare lung cancer mutation to help boost use of its drug Braftovi, which the ...
Braftovi plus Erbitux and FOLFIRI improved progression-free survival in untreated BRAF V600E metastatic colorectal cancer in the phase 3 BREAKWATER trial. A targeted treatment that includes Braftovi ...
The BRAF mutation affects a small percentage of non-small cell lung cancer (NSCLC) cases, making the cancer more difficult to treat. In recent years, advances in treatment have helped to improve ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results